Registered title, quoted from ClinicalTrials.gov
Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07874464, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed, locally advanced, unresectable stage III non-small cell lung cancer (NSCLC);
Inclusion criterion 2
Prior treatment with any anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody;
Exclusion criterion 3
Unresolved toxicity of CTCAE grade >2 from prior chemoradiotherapy;
Exclusion criterion 21
Grade ≥2 pneumonitis resulting from prior chemoradiotherapy;
Exclusion criterion 22
World Health Organization (WHO) performance status of 0 or 1;
Inclusion criterion 7
WHO performance status of 2-4;
Exclusion criterion 16
Wild-type EGFR, ALK, and ROS1;
Inclusion criterion 3
Any of the following organ or bone marrow impairments: FEV1 <800 mL; Absolute neutrophil count <1.5 × 10⁹/L; Platelet count <100 × 10⁹/L; Hemoglobin <9.0 g/dL; Creatinine clearance <50 mL/min, calculated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin >1.5 times ULN; AST and ALT >2.5 times ULN.
Exclusion criterion 17
Mixed small cell and non-small cell lung cancer histology;
Exclusion criterion 2
History of another primary malignancy within the past 5 years, except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;
Exclusion criterion 11
Female patients must not be breastfeeding;
Inclusion criterion 8
Pregnancy or breastfeeding; or male or female patients of reproductive potential who are not using effective contraception.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07874464, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male or female patients aged 18-75 years ;
- Histologically or cytologically confirmed, locally advanced, unresectable stage III non-small cell lung cancer (NSCLC);
- Wild-type EGFR, ALK, and ROS1;
- No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy;
- Availability of unstained archival tumor tissue samples sufficient for analysis;
- Life expectancy of ≥12 weeks;
- World Health Organization (WHO) performance status of 0 or 1;
- Female patients must not be breastfeeding;
- Adequate organ and bone marrow function, meeting all of the following criteria: Forced expiratory volume in 1 second (FEV1) ≥800 mL; Absolute neutrophil count ≥1.5 × 10⁹/L; Platelet count ≥100 × 10⁹/L; Hemoglobin ≥9.0 g/dL; Creatinine clearance ≥50 mL/min, calculated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin ≤1.5 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times ULN.
Exclusion Criteria:
Exclusion Criteria for Induction Therapy:
Patients meeting any of the following criteria will not receive induction therapy:
- Concurrent participation in another clinical study, unless it is an observational, non-interventional study;
- Mixed small cell and non-small cell lung cancer histology;
- Prior treatment with any anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody;
- Major surgery within 4 weeks before study entry, excluding procedures for vascular access;
- Active autoimmune disease or a history of autoimmune disease within the past 2 years;
- Active inflammatory bowel disease or a history of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis;
- History of primary immunodeficiency;
- History of organ transplantation requiring immunosuppressive therapy;
- Uncontrolled intercurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, cardiac arrhythmia, active peptic ulcer disease or gastritis, or active bleeding disorders; known hepatitis B surface antigen (HBsAg) positivity with HBV DNA >500 IU/mL, hepatitis C, or human immunodeficiency virus (HIV) infection; or psychiatric illness or social circumstances that would limit compliance with study requirements or impair the ability to provide written informed consent;
- Known history of tuberculosis, except for old, inactive pulmonary tuberculosis;
- History of another primary malignancy within the past 5 years, except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;
- Pregnancy or breastfeeding; or male or female patients of reproductive potential who are not using effective contraception.
Exclusion Criteria for Concurrent Chemoradiotherapy After Induction Therapy:
- Patients meeting any of the following criteria will not proceed to concurrent chemoradiotherapy:
- Development of distant metastases;
- Locoregional disease progression that, in the judgment of the radiation oncologist, precludes definitive chemoradiotherapy because normal tissue dose constraints cannot be met;
- WHO performance status of 2-4;
- Any of the following organ or bone marrow impairments: FEV1 <800 mL; Absolute neutrophil count <1.5 × 10⁹/L; Platelet count <100 × 10⁹/L; Hemoglobin <9.0 g/dL; Creatinine clearance <50 mL/min, calculated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin >1.5 times ULN; AST and ALT >2.5 times ULN.
Exclusion Criteria for Consolidation Immunotherapy After Concurrent Chemoradiotherapy:
- Patients meeting any of the following criteria will not proceed to consolidation immunotherapy:
- Disease progression during concurrent chemoradiotherapy;
- Use of immunosuppressive medication within 28 days before the first dose of dual immunotherapy, except for intranasal or inhaled corticosteroids at physiological doses, or systemic corticosteroids at doses not exceeding 10 mg/day of prednisone or equivalent. Corticosteroids used to manage chemoradiotherapy-related toxicity are permitted;
- Unresolved toxicity of CTCAE grade >2 from prior chemoradiotherapy;
- Grade ≥2 pneumonitis resulting from prior chemoradiotherapy;
- Any previous grade ≥3 immune-related adverse event (irAE), or any unresolved irAE of grade >1.
Quoted from ClinicalTrials.gov, NCT07874464, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07874464, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.